Newronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of Care

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Newronika

More Like This

PR Newswire associated0

Newronika Receives CE Mark Approval for AlphaDBS, Advancing Adaptive Deep Brain Stimulation for Parkinson's Disease

PR Newswire associated0

Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate U.S. Clinical Trial of Adaptive DBS System

PR Newswire associated0

Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform

PR Newswire associated0

Newronika Announces First Participant Implanted in ADVENT Pivotal Study

PR Newswire associated0

Newronika Appoints Keith Carlton as Executive Chairman to Reinforce Strategic Leadership

PR Newswire associated0

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally

PR Newswire associated0

Cumulus Neuroscience Presents Data at the ISCTM 2026 Autumn Conference

WCS: wise cortical strip

WISE Closes Oversubscribed Series D Financing Round of €30 Million, Welcoming ENEA Tech and Biomedical as Strategic New Investor